Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about deciding whether a skin spot needs checking?
What should I ask before trying to name a skin spot?
Start Here: A “Spot” Is Not a Diagnosis
People use the word spot to describe almost anything on the skin: a mole, freckle, rough patch, pimple, scab, scar, blood-vessel growth, age spot, cyst, or skin cancer. Dermatologists often use the broader word lesion, which simply means an area of skin that looks or feels different from the skin around it.
The first useful question is therefore not, “Which cancer is this?” It is:
Does this lesion have enough concerning information that it should be examined, monitored in a defined way, or biopsied?
That is a triage question. It protects patients from two common mistakes:
- assuming every unusual lesion is cancer; and
- assuming an ordinary-looking lesion must be harmless.
Benign seborrheic keratoses, dermatofibromas, angiomas, scars, inflamed follicles, and rashes can look frightening. Melanoma, basal cell carcinoma, and squamous cell carcinoma can look deceptively calm.2–5
Which changes make a skin spot worth showing a clinician?
Start With Change, Not Fear
Cancer is growth that has escaped the body's normal controls. On the skin, that may produce visible or palpable change. The most useful clues are often dynamic:
- new growth after a long period of stability;
- enlargement, elevation, or a new color;
- a surface that repeatedly crusts, bleeds, or breaks down;
- pain, tenderness, itching, numbness, or another new symptom;
- a lesion that returns after seeming to heal; or
- one spot that looks unlike the person's usual pattern.
Change does not prove cancer. Pimples, insect bites, eczema, trauma, and benign growths change too. The point is that meaningful change raises the value of an examination.
| Pattern | Why it matters | Practical response |
|---|---|---|
| New and continuing to grow | Persistent growth is different from a brief inflammatory flare | Arrange evaluation if it does not follow an expected benign course |
| Repeated bleeding or ulceration | Recurrent surface breakdown can occur in BCC, SCC, melanoma, or trauma | Do not repeatedly treat the surface without explaining the cause |
| Pain, tenderness, numbness, or unusual firmness | Symptoms and touch may signal deeper involvement or inflammation | Seek an in-person assessment rather than relying only on a photo |
| Ugly duckling | A lesion that differs from the patient's background pattern may be more informative than a fixed checklist | Compare it with the rest of your skin and show the difference to a clinician |
| Rapidly raised or nodular growth | Some aggressive lesions grow vertically and may not satisfy classic ABCDE rules | Arrange prompt assessment rather than casual home monitoring |
Can ABCDE and the ugly-duckling idea catch every concerning spot?
Use ABCDE—Then Look Beyond It
ABCDE is a memory aid for pigmented lesions:
- Asymmetry — one half does not match the other.
- Border — irregular, blurred, or notched edges.
- Color — multiple colors or uneven color distribution.
- Diameter — larger lesions may be more concerning, but melanoma can be smaller than 6 mm.
- Evolution — meaningful change over time.
In pooled studies of selected lesions, visual melanoma checklists had sensitivity near 83% and specificity near 88%.1 Those numbers do not turn ABCDE into a home rule-out test. In plain English, a checklist can miss melanoma and can also flag benign lesions.
The ugly-duckling rule
The ugly-duckling idea is personal rather than fixed: a lesion that looks unlike your other moles deserves attention even if it is small or fairly symmetric.2
What ABCDE can miss
Nodular, amelanotic, and small-diameter melanomas may lack the classic pattern. Some are pink or skin-colored. Some are raised and firm. Some change rapidly rather than gradually.1,6
What can common skin cancers look like?
What Common Skin Cancers May Look Like
No appearance makes the diagnosis by itself, but knowing the broad patterns helps patients recognize when evaluation is reasonable.
| Diagnosis | Possible warning patterns | Important limitation |
|---|---|---|
| Melanoma | Evolving or ugly-duckling mole; irregular pigment; new dark nail band; pink, red, skin-colored, raised, or fast-growing lesion | Some melanomas are small, symmetric, or colorless |
| Basal cell carcinoma | Pearly or translucent bump; small surface blood vessels; rolled edge; recurrent ulcer; persistent eczema-like patch; scar-like area | BCC can resemble a pimple, dermatitis, scar, or benign growth3,4 |
| Cutaneous squamous cell carcinoma | Firm, crusted, scaly, tender, ulcerated, bleeding, or rapidly enlarging lesion | These features are nonspecific and can overlap with benign inflammation3,5 |
| Benign lesion | Stable mole, seborrheic keratosis, angioma, dermatofibroma, cyst, scar, or inflammatory patch | Benign lesions can change when irritated, and cancer can mimic them |
What this means for you
Use appearance to decide whether a lesion deserves attention, not to declare a diagnosis. A dermatologist combines surface pattern with time, symptoms, touch, the rest of the skin, and sometimes tissue.
When does a sore that does not heal need evaluation?
A Sore That Does Not Heal
“Nonhealing” does not mean that every scratch lasting a few weeks is cancer. Skin healing varies with depth, friction, infection, circulation, immune status, and repeated picking.
The concern rises when a lesion:
- breaks down repeatedly in the same place;
- bleeds with little or no trauma;
- forms a crust that returns after it comes off;
- has a pearly, rolled, firm, or enlarging edge;
- persists despite reasonable treatment for the suspected benign condition; or
- develops pain, numbness, rapid growth, or fixation.
Repeated breakdown, recurrent crusting, or bleeding deserves clinical assessment because common skin cancers can present this way, although the finding is not specific.
There is no single validated number of days that proves a sore is cancer. Persistence matters most when the lesion does not behave like the presumed explanation.
How urgently should a concerning skin spot be evaluated?
How Urgent Is the Evaluation?
Most concerning skin lesions are not emergency-room problems. They do, however, deserve a timeline that matches the concern.
| Situation | Reasonable timing | Why |
|---|---|---|
| Rapid growth, spontaneous bleeding, ulceration, new pain, numbness, weakness, or a firm fixed lesion | Prompt professional evaluation | Delay can matter when a lesion is behaving aggressively or threatening function |
| A clearly evolving or ugly-duckling lesion without acute symptoms | Timely scheduled evaluation | Change deserves assessment even without emergency features |
| A mildly atypical flat lesion chosen by a dermatologist for monitoring | Exact short interval with reproducible imaging | Monitoring is a clinical plan, not indefinite waiting9 |
| A stable lesion with a confident benign pattern | Routine follow-up or reassurance | Not every lesion requires biopsy |
Watching is not a neutral choice. It is safe only when the initial concern is low enough, the image is reproducible, the interval is defined, and the patient will return.
What can a photograph show, and what can it miss?
When a Photograph Helps—and When It Is Not Enough
Good photographs can document change and help a dermatologist triage urgency. Useful images show scale, several angles, and consistent lighting.
An image cannot always show:
- firmness or fixation;
- precise surface texture;
- tenderness;
- depth beneath the skin;
- the pattern of the patient's other lesions; or
- regional lymph nodes when those matter.
Teledermatology can improve access, but image quality and the absence of touch limit what it can answer.7 It works best as a bridge to the correct next step, not as a promise that no further examination is needed.
If a phone application labels a changing spot low risk, arrange professional assessment rather than relying on the application result.
Why can’t a consumer app clear a concerning spot?
Why a Consumer App Cannot Clear a Spot
In a Cochrane review of smartphone applications for melanoma triage, reported sensitivity ranged from 7% to 73%. In the evaluated datasets, that meant 27% to 93% of melanomas were labeled low risk.8
What that evidence means
Some studied apps missed most melanomas. The technology and evidence change over time, but the patient-safety rule is stable: a reassuring app result should never overrule a concerning change.
An app may remind someone to look. It cannot examine the whole skin, feel the lesion, compare subtle patterns with expert training, or perform a biopsy.
What happens during a dermatology visit for a concerning spot?
What Happens at the Dermatology Visit
A dermatologist combines several layers of information:
- The story. When did the lesion appear? How did it change? Does it bleed, hurt, itch, or heal and recur?
- The patient's background pattern. Is this an ugly duckling or one of many matching benign lesions?
- Touch. Is it firm, mobile, fixed, tender, scaly, or deeper than it appears?
- Dermoscopy. Are there subsurface pigment or vascular structures that alter concern?
- The consequence of delay. Would watching create meaningful risk if the first impression were wrong?
- The next action. Reassure, treat, photograph, monitor, biopsy, or coordinate additional care.
Dermoscopy improves melanoma detection in trained hands. In a Cochrane review, estimated sensitivity increased from about 76% with unaided visual inspection to about 92% with dermoscopy at a fixed specificity of 80%.10,11
What that evidence means
The dermatologist is not simply looking harder. A trained examination adds new visual information and integrates it with context. Even then, pathology remains the reference standard when a definitive tissue diagnosis is needed.
When does monitoring fit, and when is biopsy favored?
When Monitoring Fits—and When Biopsy Fits
| Clinical situation | Monitoring may fit | Biopsy is usually favored |
|---|---|---|
| Flat mildly atypical mole | When dermoscopic concern is low, imaging is reproducible, and short follow-up is reliable | When it evolves, develops symptoms, or no longer fits the low-concern pattern |
| Raised or nodular lesion | Rarely as casual home observation | When new, growing, firm, bleeding, symptomatic, or clinically discordant |
| Possible BCC or SCC | Selected lesions with a confident alternative diagnosis | Persistent, recurrently ulcerated, rapidly growing, tender, or otherwise suspicious lesions |
| Possible melanoma | Only in narrowly selected expert-monitoring scenarios | When the lesion is sufficiently suspicious that definitive tissue information matters |
Short-term digital dermoscopic monitoring studies support rechecking carefully selected, mildly atypical flat lesions. The reassuring performance reported in that narrow setting does not apply to nodular, painful, rapidly changing, bleeding, or otherwise high-concern lesions.9
What does a biopsy answer when a spot remains concerning?
If a Biopsy Is Needed
A biopsy removes tissue so a dermatopathologist can examine cells and architecture under a microscope. Histopathology is the reference standard when a definitive diagnosis is required.6,12
If melanoma is possible, the preferred biopsy usually removes the full visible lesion with narrow clinical margins and enough depth to measure it when that can be done safely. Large facial, nail, palm, or sole lesions may require a carefully targeted partial sample.6,13
Not every benign-looking spot needs biopsy. The decision depends on pretest concern, the consequence of being wrong, and whether monitoring can be done safely.
How do common spot examples change the next step?
Four Common Examples
“This mole has always been dark, but it has not changed.”
Color alone does not determine risk. Compare it with the rest of your moles, its history, border, structure, and whether it is truly stable. A stable lesion can still deserve a baseline evaluation if it is an ugly duckling or difficult to assess.
“This pink bump bleeds when I wash my face.”
Repeated bleeding from a persistent pink or pearly bump can fit BCC, SCC, or a benign irritated lesion. The recurrence makes professional assessment reasonable.
“An app says the spot is low risk.”
Treat the app result as irrelevant if the lesion is changing or concerning. Published app studies demonstrate that low-risk labels can be wrong.8
“My dermatologist photographed it and asked me to return in three months.”
That can be a valid plan when the lesion is flat, only mildly atypical, documented carefully, and low enough risk that a short delay is safe. Return sooner if the lesion changes or develops symptoms.
What does the evidence say about checklists and skin-spot apps?
Evidence by the Numbers
Evidence by the NumbersABCDE helps, but it cannot clear a spot
ABCDE helps, but it cannot clear a spot
About 83% sensitivity and 88% specificity
- Population
- Lesion-selected visual melanoma studies included in a Cochrane review
- Outcome
- Pooled diagnostic performance of visual melanoma checklists
- Time horizon
- At the time of lesion assessment
What it means: ABCDE is a useful memory aid for noticing concern, but it can miss melanoma and can also flag benign lesions.
Limitations: Study populations and methods differed, and these estimates do not make ABCDE a safe home rule-out test.
References: 1
Evidence by the NumbersA phone app cannot safely rule out melanoma
A phone app cannot safely rule out melanoma
7% to 73% sensitivity
- Population
- Melanoma-triage smartphone-app studies included in a Cochrane review
- Outcome
- Across evaluated datasets, 27% to 93% of melanomas were labeled low risk
- Time horizon
- At the photographed-lesion assessment
What it means: A reassuring app result should never overrule meaningful change, symptoms, or clinician concern.
Limitations: The studies were heterogeneous and at high risk of bias; the range is a warning about unreliability, not a forecast for a specific app.
References: 8
Evidence by the NumbersDefined monitoring can be safe for the right lesion
Defined monitoring can be safe for the right lesion
99.2% benign reliability
- Population
- Carefully selected mildly atypical flat lesions without high-risk features
- Outcome
- No change after a three-month digital dermoscopic interval strongly predicted a benign lesion
- Time horizon
- Three months
What it means: A dermatologist may reasonably photograph and recheck a low-concern flat lesion instead of biopsying every spot immediately.
Limitations: This does not apply to nodular, symptomatic, rapidly changing, bleeding, or otherwise high-concern lesions.
References: 9
What questions should I ask about a concerning spot?
Questions Worth Asking
- Which feature makes this lesion reassuring or concerning?
- Does dermoscopy change the interpretation?
- If we monitor it, what exact interval and what change would trigger biopsy?
- If biopsy is recommended, what question must the sample answer?
- Is the biopsy deep and representative enough for the suspected diagnosis?
- Are there other spots or hidden sites that should be checked?
Frequently asked questions about concerning skin spots
Frequently Asked Questions
Can skin cancer be colorless?
Yes. Amelanotic melanoma, some basal cell carcinomas, and many squamous cell carcinomas can be pink, red, or skin-colored.
Is bleeding always cancer?
No. Trauma, irritation, and benign growths can bleed. Spontaneous or recurrent bleeding without a clear explanation deserves assessment.
Is a spot safe if it is smaller than a pencil eraser?
No size alone clears a lesion. Small melanomas occur, especially when evolution or an ugly-duckling pattern is present.1,2
Can I watch it for a few months?
Sometimes, but only when the lesion is suitable for monitoring, the image is reproducible, the interval is defined, and follow-up is reliable. Raised, painful, fast-growing, bleeding, ulcerated, or otherwise high-concern lesions should not be managed casually by waiting.9
Can a photograph prove that a lesion is benign?
Usually not. Images can help with triage and change detection, but touch, whole-skin context, dermoscopy, and pathology may be needed.
Should every unusual lesion be removed?
No. The goal is an accurate threshold. Confident benign lesions can be reassured; selected low-concern lesions can be monitored; lesions with meaningful concern should be biopsied.
What if the spot disappeared before my appointment?
Bring a dated photograph and describe what happened. Recurrent lesions, especially those that bleed or ulcerate in the same place, may still deserve assessment.
Can a dermatologist be certain without biopsy?
Sometimes a benign pattern is sufficiently characteristic for reassurance. When the diagnosis or treatment depends on microscopic information, biopsy provides the definitive tissue answer.
Who reviewed and authored this skin-spot guide?
Where should I go next in the Patient Journey?
Next Steps in the Patient Journey
Continue with the guide that best matches your next question.
Continue with the question that fits you now
References for this skin-spot guide
References
- Dinnes J, Deeks JJ, Chuchu N, et al. Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD013194. DOI: 10.1002/14651858.CD013194.
- Scope A, Dusza SW, Halpern AC, et al. The ugly duckling sign: agreement between observers. Arch Dermatol. 2008;144:58-64.
- Dinnes J, Deeks JJ, Chuchu N, et al. Visual inspection and dermoscopy for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev. 2018;12:CD011901. DOI: 10.1002/14651858.CD011901.pub2.
- Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375:673-685. DOI: 10.1016/S0140-6736(09)61196-X.
- Askari SK, Schram SE, Wenner RA, et al. Evaluation of prospective variables for distinguishing squamous cell carcinoma from keratoacanthoma. Dermatol Surg. 2007. PMID: 17258839.
- Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250. PMID: 30392755. DOI: 10.1016/j.jaad.2018.08.055.
- Chuchu N, Dinnes J, Takwoingi Y, et al. Teledermatology for diagnosing skin cancer in adults. Cochrane Database Syst Rev. 2018;12:CD013193. DOI: 10.1002/14651858.CD013193.
- Chuchu N, Takwoingi Y, Dinnes J, et al. Smartphone applications for triaging adults with skin lesions suspicious for melanoma. Cochrane Database Syst Rev. 2018;12:CD013192. PMID: 30521685. DOI: 10.1002/14651858.CD013192.
- Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol. 2008;144:502-506.
- Dinnes J, Deeks JJ, Chuchu N, et al. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD011902. DOI: 10.1002/14651858.CD011902.pub2.
- Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3:159-165. DOI: 10.1016/S1470-2045(02)00679-4.
- Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-578. PMID: 29331386. DOI: 10.1016/j.jaad.2017.10.007.
- Ahmadi O, Das M, Hajarizadeh B, Mathy JA. Impact of shave biopsy on diagnosis and management of cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol. 2021;28:6168-6178. PMID: 33782802.